Lineage Cell Therapeutics (LCTX) Change in Cash (2010 - 2026)

Lineage Cell Therapeutics has reported Change in Cash for 17 years, with the latest figure at -$4.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash fell 343.86% year-over-year to -$4.8 million; the trailing twelve-month figure through Mar 2026 stood at -$11.9 million (down 381.18% YoY), and the FY2025 full-year result was -$5.0 million, down 148.54% from the prior year.
• Change in Cash for Q1 2026 stood at -$4.8 million, down from $347000.0 in the prior quarter.
• The five-year high for Change in Cash was $22.3 million in Q1 2022, with the low at -$46.1 million in Q3 2022.
• Historically, Change in Cash has averaged -$1.2 million across 5 years, with a median of -$1.8 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Cash tumbled 3777.44% — and 2023, when it soared 354.34%.
• Lineage Cell Therapeutics' Change in Cash stood at -$13.4 million in 2022, then soared by 129.88% to $4.0 million in 2023, then surged by 352.1% to $18.0 million in 2024, then tumbled by 98.08% to $347000.0 in 2025, then sank by 1497.12% to -$4.8 million in 2026.
• The last three Change in Cash figures came in at -$4.8 million (Q1 2026), $347000.0 (Q4 2025), and -$1.8 million (Q3 2025), per Business Quant data.